You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
現代製藥(600420.SH):吲達帕胺片擬中選全國藥品集中採購
格隆匯 01-17 20:49

格隆匯1月17日丨現代製藥(600420.SH)公佈,2020年1月17日,公司全資子公司國藥集團工業有限公司(以下簡稱“國工有限”)參加了聯合採購辦公室組織的各省(自治區、直轄市)、新疆生產建設兵團共32個區的全國藥品集中採購工作。國工有限已獲得國家藥品監督管理局仿製藥質量和療效一致性評價的仿製藥品吲達帕胺片(2.5mg)擬中選本次集中採購。藥品2018年度銷售收入約4013.00萬元,佔公司2018年度營業收入約0.35%。

本次藥品集中採購是國家組織的“4+7試點”、“4+7擴圍”兩個階段後,啟動的第三個階段“4+7擴品種”(第二批國家帶量採購),在執行上要求全國各省(自治區、直轄市)、新疆生產建設兵團共32個區的醫療機構優先使用集中採購中選品種,並確保完成約定採購量。公司本次擬中選的品種為公司獲得國家藥品監督管理局仿製藥質量和療效一致性評價的仿製藥品,本次擬中選價格與原中標價格相比有一定程度下降,具體以聯採辦公佈的價格為準。

目前,國工有限已與聯採辦簽訂了《全國藥品集中採購擬中選品種備忘錄》,上述產品的購銷合同簽訂等後續事項尚具有不確定性。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account